Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)

SHA:603207 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	674.68	647.59	883.43	285.54	58.66	44.81
Short-Term Investments	-	-	-	-	1.31	5.08
Trading Asset Securities	-	-	-	2.97	108.96	158.11
Cash & Short-Term Investments	674.68	647.59	883.43	288.52	168.93	208.01
Cash Growth	-4.65%	-26.70%	206.20%	70.79%	-18.79%	84.58%
Accounts Receivable	131.13	123.97	90.29	85.39	81.88	55.82
Other Receivables	23.54	2.93	2.21	2.06	0.82	0.72
Receivables	154.67	126.9	92.5	87.46	82.69	56.55
Inventory	61.38	69.18	45.21	49.9	57.2	53.37
Other Current Assets	14.47	16.19	10.8	26.19	19.04	8.45
Total Current Assets	905.21	859.86	1,032	452.06	327.87	326.37
Property, Plant & Equipment	357.8	349.22	338.04	226.57	62.97	25.75
Long-Term Investments	-	-	-	-	-	1.27
Other Intangible Assets	22.15	22.94	24.53	26.12	27.7	29.23
Long-Term Deferred Tax Assets	5.01	4.8	3.36	2.86	2.27	2
Long-Term Deferred Charges	-	-	1.32	0.47	0.49	0.74
Other Long-Term Assets	16.5	2.65	3.26	4.58	42	0.67
Total Assets	1,307	1,239	1,402	712.65	463.3	386.02

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	30.55	38.99	23.09	19.61	27.42	16.61
Accrued Expenses	40.09	37.08	36.34	38.38	28.91	34.34
Short-Term Debt	7.66	1.12	1.65	-	-	-
Current Portion of Leases	1.72	1.06	0.67	0.42	-	-
Current Income Taxes Payable	8.98	6.09	7.13	5.33	12.5	13.71
Current Unearned Revenue	0.88	6.97	0.89	0.61	1.55	11.79
Other Current Liabilities	73.31	55.02	98.38	67.82	19.58	79.09
Total Current Liabilities	163.18	146.34	168.15	132.18	89.96	155.55
Long-Term Leases	0.1	0.32	-	0.44	0.88	1.27
Long-Term Unearned Revenue	0.05	0.05	0.07	0.08	0.09	0.1
Total Liabilities	163.33	146.71	168.21	132.7	90.94	156.92

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	160.67	160.56	160	120	120	120
Additional Paid-In Capital	492.12	489.09	478.23	69.22	65.25	61.18
Retained Earnings	496.36	450.26	596.01	390.73	187.11	47.93
Treasury Stock	-5.83	-7.15	-	-	-	-
Shareholders' Equity	1,143	1,093	1,234	579.95	372.36	229.11
Total Liabilities & Equity	1,307	1,239	1,402	712.65	463.3	386.02

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	9.49	2.5	2.32	0.86	0.88	1.27
Net Cash (Debt)	665.2	645.08	881.11	287.65	168.05	206.74
Net Cash Growth	-5.82%	-26.79%	206.31%	71.17%	-18.71%	83.45%
Net Cash Per Share	4.15	4.01	6.57	2.40	1.40	1.72
Filing Date Shares Outstanding	159.83	160.82	160.56	160	120	120
Total Common Shares Outstanding	159.83	160.56	160	120	120	120
Working Capital	742.02	713.52	863.79	319.89	237.9	170.83
Book Value Per Share	7.15	6.81	7.71	4.83	3.10	1.91
Tangible Book Value	1,121	1,070	1,210	553.84	344.66	199.88
Tangible Book Value Per Share	7.01	6.66	7.56	4.62	2.87	1.67
Buildings	13.38	13.22	26.35	26.35	26.35	25.62
Machinery	41.49	41	36.94	35.52	35.19	32.62
Construction In Progress	345.24	336.51	329.17	216.53	50.04	12.67

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error